Hepatitis A, B, and C: Virology, Pathogenesis, and Pharmacotherapeutic Management

Introduction

Viral hepatitis represents a major global public health challenge, with the hepatotropic viruses A, B, and C constituting the most clinically significant etiologies. These viruses are taxonomically distinct, with differing routes of transmission, natural histories, and potentials for chronicity, yet they share the common endpoint of hepatic inflammation and injury. The pharmacological management of these infections has undergone a profound transformation, particularly for hepatitis B and C, moving from non-specific immunomodulators to targeted antiviral agents. An understanding of the virology, immunopathogenesis, and pharmacokinetic principles underlying these therapies is fundamental for rational therapeutic decision-making in clinical practice.

The historical identification of these agents, from the early recognition of “infectious” and “serum” hepatitis to the specific discovery of each viral particle, has directly informed preventive and therapeutic strategies. The development of effective vaccines for hepatitis A and B stands as a landmark achievement in prophylactic medicine. In contrast, the absence of a vaccine for hepatitis C has placed greater emphasis on antiviral drug development, culminating in curative regimens. The pharmacological approach to these viruses is a core component of hepatology, infectious disease, and public health, requiring integration of virologic, immunologic, and pharmacokinetic knowledge.

The primary learning objectives for this chapter are:

• To differentiate the virologic characteristics, transmission routes, and clinical courses of hepatitis A, B, and C viruses.
• To explain the molecular mechanisms of action, pharmacokinetic profiles, and resistance patterns of antiviral agents used in the management of chronic hepatitis B and C.
• To analyze the principles guiding treatment initiation, regimen selection, and monitoring of therapy for chronic viral hepatitis.
• To evaluate the role of immunoprophylaxis, including vaccines and immunoglobulins, in the prevention of hepatitis A and B.
• To apply pharmacological knowledge to clinical case scenarios involving therapeutic decision-making and problem-solving.

Fundamental Principles

The foundational understanding of viral hepatitis rests upon several core concepts. First is the principle of viral tropism; each of these viruses exhibits a specific predilection for hepatocytes, though the mechanisms of entry and replication differ substantially. Second is the host immune response, which is responsible for both viral clearance and the pathogenesis of liver injury. The balance between an effective cytotoxic T-lymphocyte response and viral persistence defines the outcome of infection. Third is the concept of chronicity, defined as the persistence of viral infection for more than six months. This is a rare outcome for hepatitis A but is a central feature in the natural history of hepatitis B and C, leading to risks of cirrhosis and hepatocellular carcinoma.

Core Definitions and Terminology

Key terminology must be precisely understood. Acute hepatitis refers to the initial infection, often symptomatic, with elevated serum aminotransferase levels. Fulminant hepatic failure denotes a severe, life-threatening form of acute hepatitis with encephalopathy and impaired synthetic function. Chronic hepatitis is characterized by persistent necroinflammation, potentially leading to fibrosis. Cirrhosis is the end-stage of fibrosis with nodular regeneration and architectural distortion. Virologic terms are equally critical: HBsAg (hepatitis B surface antigen) indicates current infection, while anti-HBs signifies immunity. HBeAg and anti-HBe are serologic markers of viral replication activity in hepatitis B. For hepatitis C, the sustained virologic response (SVR), defined as an undetectable viral load 12 or 24 weeks after completing therapy, is synonymous with cure. Direct-acting antivirals (DAAs) are oral agents that target specific non-structural proteins of the hepatitis C virus.

Detailed Explanation

The following sections provide a detailed exposition of the virology, pathogenesis, and pharmacology pertinent to each viral agent.

Hepatitis A Virus (HAV)

Hepatitis A virus is a positive-sense, single-stranded RNA virus classified within the Picornaviridae family. It is transmitted primarily via the fecal-oral route, often through contaminated food or water, and is highly endemic in regions with poor sanitation. The virus is non-enveloped, conferring environmental stability and resistance to detergents and drying. Following ingestion, the virus replicates within hepatocytes and is secreted into bile, leading to high concentrations in feces. Liver injury is mediated primarily by the host’s cellular immune response against infected hepatocytes, rather than direct viral cytopathy.

The infection is invariably acute and self-limiting, with no chronic carrier state. Clinical severity tends to increase with age. Pharmacological management is solely supportive, as no specific antiviral therapy exists. The cornerstone of control is prevention through vaccination and, for post-exposure prophylaxis, the administration of immune globulin.

Hepatitis B Virus (HBV)

Hepatitis B virus is a partially double-stranded DNA virus belonging to the Hepadnaviridae family. It is one of the most common chronic viral infections globally. Transmission occurs via percutaneous or mucosal exposure to infected blood or body fluids, including through sexual contact, perinatal exposure, and injection drug use. The viral lifecycle is unique and involves a reverse transcription step. The virus enters hepatocytes via the sodium taurocholate co-transporting polypeptide (NTCP) receptor. The covalently closed circular DNA (cccDNA) forms a stable mini-chromosome in the host nucleus, serving as the transcriptional template for all viral mRNAs and pregenomic RNA. This cccDNA reservoir is central to viral persistence and the challenge of achieving a complete cure.

The clinical spectrum ranges from an asymptomatic acute infection to a chronic carrier state, which develops in approximately 90% of perinatally infected infants and 5-10% of infected adults. Chronic infection is stratified into phases: immune-tolerant, immune-active (HBeAg-positive or negative), inactive carrier, and reactivation. The risk of progression to cirrhosis and hepatocellular carcinoma is significant and correlates with the level of ongoing viral replication and hepatic inflammation.

Pharmacology of Hepatitis B Antivirals

Therapeutic agents for chronic hepatitis B aim to suppress viral replication, thereby reducing hepatic inflammation, fibrosis progression, and the risk of carcinogenesis. The two main classes are nucleos(t)ide analogues (NAs) and pegylated interferon-alpha (PegIFN-α).

Nucleos(t)ide Analogues (NAs): These are oral prodrugs that, upon intracellular phosphorylation, compete with natural nucleos(t)ides for incorporation into the elongating viral DNA chain by the HBV polymerase (reverse transcriptase). Incorporation results in premature chain termination. First-generation agents like lamivudine and adefovir are limited by high rates of resistance. High-barrier-to-resistance NAs are now preferred: entecavir, tenofovir disoproxil fumarate (TDF), and tenofovir alafenamide (TAF). These agents exhibit potent viral suppression with negligible resistance rates in treatment-naïve patients over long-term use.

Their pharmacokinetics are characterized by oral bioavailability, renal excretion (primarily for TDF and TAF, necessitating dose adjustment in renal impairment), and minimal metabolism by cytochrome P450 enzymes. A key pharmacodynamic consideration is the need for long-term, often indefinite, therapy, as cessation can lead to virologic relapse and severe hepatitis flares. Viral kinetic modeling of HBV DNA decline during therapy typically shows a biphasic pattern: a rapid first-phase decline representing clearance of virions from the blood, followed by a slower second-phase decline representing loss of infected hepatocytes.

Pegylated Interferon-alpha (PegIFN-α): This immunomodulator is administered via weekly subcutaneous injection. Its mechanism is complex, involving induction of intracellular antiviral proteins, enhancement of major histocompatibility complex antigen presentation, and modulation of the adaptive immune response. Its use is limited by a subcutaneous route, a finite treatment duration (typically 48 weeks), and a significant side-effect profile including flu-like symptoms, cytopenias, and psychiatric effects. Response rates are modest, but a successful response (HBeAg seroconversion or HBsAg loss) is often durable after treatment cessation.

Hepatitis C Virus (HCV)

Hepatitis C virus is a positive-sense, single-stranded RNA virus of the Flaviviridae family. It exhibits marked genetic heterogeneity, with seven major genotypes and numerous subtypes that influence treatment selection. Transmission is primarily parenteral. Unlike HBV, HCV does not integrate into the host genome and has no DNA intermediate, yet it establishes chronic infection in 55-85% of exposed individuals, largely due to its ability to evade host innate and adaptive immune responses.

The viral polyprotein is cleaved by host and viral proteases into structural (core, E1, E2) and non-structural (NS2, NS3, NS4A, NS4B, NS5A, NS5B) proteins. The non-structural proteins form the replication complex and are the targets for direct-acting antivirals.

Pharmacology of Direct-Acting Antivirals (DAAs) for Hepatitis C

The development of DAAs has revolutionized HCV therapy, enabling all-oral, well-tolerated regimens with cure rates exceeding 95%. These agents are classified by their target viral protein.

Modern regimens combine two or three DAAs from different classes to achieve synergistic antiviral activity and a high barrier to resistance. Treatment duration is typically 8 to 12 weeks. The pharmacokinetic principle of achieving sustained intrahepatic concentrations above the inhibitory concentration is critical for efficacy. Viral kinetics under DAA therapy are rapid, often showing a >3 log₁₀ decline in HCV RNA within the first week. The goal of therapy is a sustained virologic response (SVR), which is associated with halting disease progression, regression of fibrosis, and reduced hepatic and extrahepatic morbidity.

Factors Affecting Treatment Response and Outcomes

Several factors influence the selection and success of antiviral therapy for hepatitis B and C. For HBV, these include the phase of infection (HBeAg status, ALT level, HBV DNA level), the presence of advanced fibrosis or cirrhosis, and prior treatment history. For HCV, the most critical factors are the viral genotype and the presence of baseline resistance-associated substitutions (RASs). Other factors common to both include the degree of hepatic impairment (Child-Pugh class), renal function, potential for drug-drug interactions (particularly with DAAs and immunosuppressants or antiepileptics), and patient comorbidities. Adherence to the prescribed regimen is a paramount modifiable factor for achieving optimal outcomes.

Clinical Significance

The pharmacological management of viral hepatitis is directly linked to the prevention of long-term hepatic and extrahepatic sequelae. Effective suppression of HBV replication with NAs reduces the incidence of cirrhosis and hepatocellular carcinoma, although the risk is not eliminated, particularly in those with established cirrhosis at treatment initiation. Therefore, lifelong surveillance for hepatocellular carcinoma is often required even in virologically suppressed patients. For HCV, achieving SVR is associated with a >70% reduction in the risk of hepatocellular carcinoma, a reduction in liver-related mortality, and improvement in extrahepatic manifestations such as cryoglobulinemic vasculitis and insulin resistance.

The relevance to drug therapy extends beyond antivirals. Patients with advanced liver disease from viral hepatitis may have altered pharmacokinetics for many drugs due to changes in hepatic blood flow, cytochrome P450 activity, and protein binding. Furthermore, the initiation of immunosuppressive therapy (e.g., for oncology or rheumatology) in a patient with chronic viral hepatitis can lead to reactivation of viral replication and severe hepatitis, necessitating prophylactic antiviral therapy. This is a critical pharmacovigilance consideration.

Prevention: Vaccines and Immunoglobulins

Pharmacological prevention is highly effective for hepatitis A and B. Hepatitis A vaccine consists of inactivated whole virus and provides long-term immunity after a two-dose series. Hepatitis B vaccine is a recombinant HBsAg protein, administered as a three-dose series. Immunogenicity is high in healthy individuals, but may be reduced in older adults, smokers, and the immunocompromised. Post-vaccination serologic testing is recommended for healthcare workers and chronic kidney disease patients. Hepatitis B immune globulin (HBIG) provides passive immunity and is used for post-exposure prophylaxis (e.g., needlestick injuries) and in the prevention of perinatal transmission when given in conjunction with the vaccine series to the newborn. No vaccine exists for hepatitis C, making treatment-as-prevention and harm-reduction strategies paramount.

Clinical Applications and Examples

The application of pharmacological principles is best illustrated through clinical scenarios.

Case Scenario 1: Treatment-Naïve Chronic Hepatitis B

A 45-year-old male is diagnosed with HBeAg-positive chronic hepatitis B. His ALT is 85 U/L (upper limit of normal 40), HBV DNA is 10⁷ IU/mL, and liver biopsy shows moderate necroinflammation and portal fibrosis. He has normal renal function.

Pharmacotherapeutic Approach: Treatment is indicated based on elevated ALT, high HBV DNA, and evidence of significant histological disease. Both PegIFN-α and NAs are potential options. PegIFN-α could be considered given his age and HBeAg-positive status, as it offers a chance of finite therapy with HBeAg seroconversion. However, due to its side effects and contraindications, a high-barrier-to-resistance NA is often preferred. Entecavir 0.5 mg daily or TAF 25 mg daily would be appropriate first-line choices. TDF might be avoided due to potential long-term renal and bone toxicity, though it remains effective. The patient must be counseled that NA therapy is likely long-term. Monitoring would include HBV DNA and ALT every 3-6 months to confirm virologic suppression (target: HBV DNA undetectable or <20 IU/mL), HBeAg/anti-HBe status annually, and surveillance for hepatocellular carcinoma with ultrasound every 6 months due to his age and fibrosis.

Case Scenario 2: Hepatitis C Genotype 1a with Compensated Cirrhosis

A 58-year-old female with a history of injection drug use 20 years prior presents with fatigue. She is found to have HCV RNA of 1.2 × 10⁶ IU/mL, genotype 1a. Non-invasive elastography indicates cirrhosis (F4). Her Child-Pugh score is A5 (compensated). She takes amlodipine for hypertension.

Pharmacotherapeutic Approach: Treatment is indicated for all patients with chronic HCV infection, regardless of fibrosis stage, given the availability of curative therapy. The presence of compensated cirrhosis necessitates a regimen with a high barrier to resistance and may influence treatment duration. A preferred regimen for genotype 1a with compensated cirrhosis is glecaprevir/pibrentasvir for 8 weeks (if no prior treatment) or sofosbuvir/velpatasvir/voxilaprevir for 12 weeks. An alternative is ledipasvir/sofosbuvir for 12 weeks, but testing for baseline NS5A RASs may be considered. A critical step is a drug interaction check. Glecaprevir is a CYP3A4 and P-gp substrate/inhibitor, but no significant interaction is expected with amlodipine. The patient would be monitored for HCV RNA at baseline, week 4 of treatment (optional), at the end of treatment, and 12 weeks post-treatment to confirm SVR. She would also require ongoing hepatocellular carcinoma surveillance every 6 months despite achieving SVR, due to the established cirrhosis.

Case Scenario 3: Post-Exposure Prophylaxis

A medical student sustains a needlestick injury from a hollow-bore needle used on a patient whose HBsAg status is unknown (but later found to be positive). The student completed the hepatitis B vaccine series 5 years ago but has never had post-vaccination serology checked.

Pharmacological Management: The approach depends on the exposed person’s vaccination and immune status. Since the student’s anti-HBs titer is unknown, it should be tested immediately. If the titer is ≥10 mIU/mL, no further action is needed. If the titer is <10 mIU/mL or results are pending, hepatitis B immune globulin (HBIG) 0.06 mL/kg should be administered intramuscularly as soon as possible (ideally within 24 hours, up to 7 days). Furthermore, a booster dose of hepatitis B vaccine should be given concurrently at a separate site. This combined active-passive immunoprophylaxis is highly effective in preventing infection.

Summary and Key Points

• Hepatitis A, B, and C are caused by distinct viruses with differing structures, transmission routes, and potentials for chronic infection. Hepatitis A is an acute, self-limiting infection preventable by vaccine.
• Chronic hepatitis B management relies on long-term suppression with high-barrier-to-resistance nucleos(t)ide analogues (entecavir, tenofovir alafenamide) or a finite course of pegylated interferon-alpha. Viral cccDNA persistence precludes a simple cure with current therapies.
• Chronic hepatitis C is now curable in over 95% of patients with all-oral, well-tolerated regimens of direct-acting antivirals (DAAs) targeting the NS3/4A protease, NS5A protein, and NS5B polymerase. Treatment selection is guided by HCV genotype, prior treatment history, and presence of cirrhosis.
• Pharmacokinetic considerations, particularly drug-drug interactions (especially with DAA regimens), renal dosing for certain NAs, and adherence, are critical for therapeutic success.
• Prevention through vaccination is highly effective for hepatitis A and B. Post-exposure prophylaxis for HBV involves HBIG and/or vaccine based on the exposed individual’s immune status.
• Even after successful virologic control or cure, patients with advanced fibrosis or cirrhosis require ongoing surveillance for hepatocellular carcinoma.

Clinical Pearls:

• In chronic hepatitis B, do not discontinue nucleos(t)ide analogue therapy abruptly due to the risk of severe reactivation hepatitis.
• Prior to initiating DAA therapy for hepatitis C, a comprehensive medication reconciliation is mandatory to assess for potential drug-drug interactions.
• The success of HCV therapy is measured by the sustained virologic response (SVR), which is durable and equivalent to a virologic cure.
• Vaccination against hepatitis A and B should be assessed and offered to all susceptible patients with chronic liver disease from any etiology.

References

1. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
2. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.
3. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.
4. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
5. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.
6. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill Education; 2023.